Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer
- 31 May 2009
- journal article
- Published by Elsevier BV in Biomaterials
- Vol. 30 (15), 2912-2918
- https://doi.org/10.1016/j.biomaterials.2009.02.010
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- The biocompatibility of quantum dot probes used for the targeted imaging of hepatocellular carcinoma metastasisBiomaterials, 2008
- Advances in the application of quantum dots in tumor markers investigationThe Chinese-German Journal of Clinical Oncology, 2008
- Predictive markers in breast cancer – the presentHistopathology, 2007
- The effect of chromosome 17 polysomy on HER-2/neu status in breast cancerJournal of Clinical Pathology, 2007
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene, 2007
- Quantum Dots for Molecular Pathology: Their Time Has ArrivedThe Journal of Molecular Diagnostics, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment IIHistopathology, 2006
- Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the WorldJournal of Clinical Oncology, 2006